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Measurement of Reduced Glutathione (GSH) in Human
Brain Using LCModel Analysis of Difference-Edited
Spectra
Melissa Terpstra, Pierre-Gilles Henry, and Rolf Gruetter*
The concentration of reduced glutathione (GSH), an antioxidant,
may be altered in various brain diseases. MEGA-PRESS was used
to edit for the 1H NMR signal from GSH in the occipital lobe of
12 normal humans. In all studies, GSH was clearly detected with a
spectral pattern consistent with spectra acquired from a phantom
containing GSH. Retention of singlet resonances in the subspec-
tra, a key advantage of this difference-editing technique, provided
an unambiguous reference for the offset and phase of the edited
signal. Linear combination model (LCModel) analysis provided an
unbiased means for quantifying signal contribution from edited
metabolites. GSH concentration was estimated from the in vivo
spectra as 1.3  0.2 mol/g (mean  SD, n  12). Magn Reson
Med 50:19–23, 2003. © 2003 Wiley-Liss, Inc.
Key words: GSH; human; MEGA; LCModel
Glutathione (-glutamyl cysteinyl glycine) is a major intra-
cellular antioxidant (1). Present at high levels (1–5 mM)
in animal cells, glutathione cycles between a reduced thiol
form (GSH) and an oxidized form (GSSG). The ratio of GSH
to GSSG in most cells is greater than 500:1 (2), so GSH is,
under most circumstances, the most concentrated form of
glutathione. GSH plays a fundamental role in the detoxi-
fication of reactive oxygen species, which is critical to the
normal function of the human brain (3). Compromised
astroglial GSH metabolism may contribute to oxidative
stress, which has been implicated in many neurological
disorders, as well as in schizophrenia (3,4).
Despite the high reported concentration of GSH in the
CNS (5), its measurement by 1H NMR spectroscopy has
been elusive, partly because of spectral overlap with other
signals from more concentrated compounds. Recently, us-
ing LCModel analysis of short echo time spectra, a con-
centration of GSH on the order of 1 mol/g was reported in
rat brain (6), which was reduced in quinolinic acid-le-
sioned rat striatum (7) in agreement with biochemical
reports (8). In the human brain, the detection of GSH using
spectral editing based on double quantum coherence fil-
tering has been reported (9,10). The strongly coupled cys-
teine -CH2 protons of GSH resonating at 2.95 ppm, which
are J-coupled to cysteine -CH (4.56 ppm), were found to
be suitable for edited detection. Brain metabolites resonat-
ing in the vicinity of 2.95 ppm include: (phospho)creatine
(3.03 ppm), aspartate (2.82 ppm), GABA (3.01 ppm), and
macromolecules (2.98 ppm) (6).
While the single shot nature of multiple-quantum edit-
ing is advantageous, editing based on J-difference spectros-
copy offers the advantage of unambiguous determination
of the frequency and phase in the edited spectra from the
simultaneously detected singlet resonances in the non-
edited subspectra. In addition, the singlet resonances in
the subspectra can be exploited for frequency and phase
correction of each acquisition, which results in improved
spectral quality (11,12). To confirm earlier reports of a
measurable GSH signal in the CNS (6,13), MEGA-PRESS
(14), a difference-editing technique, was adapted for de-
tection of the cysteinyl resonance of GSH.
Spectral editing for the strongly coupled resonances of
GSH can result in complicated, modulated spectral pat-
terns that are difficult to integrate and thus quantify. This
difficulty was overcome by the novel application of LC-
Model analysis (15) to edited spectra. LCModel used the
unique spectral pattern of GSH, measured in vitro with the
editing method, to determine the contribution of GSH to
the edited in vivo spectrum. Because the aspartyl reso-
nances of NAA were coedited with GSH, and because they
resonate nearby with comparable intensity, the model
spectrum of NAA was also included. These coedited res-
onances of NAA also served as an internal concentration
reference.
METHODS
Nine normal volunteers (six male, three female, average
age 25 years), three of whom were studied twice, gave
informed consent for this study, which was conducted
according to procedures approved by the Institutional Re-
view Board. All experiments were performed with a 4 T,
90 cm bore magnet (Oxford Magnet Technology, Oxford,
UK) interfaced to a Varian INOVA spectrometer (Varian,
Palo Alto, CA) equipped with gradients capable of switch-
ing to 40mT/m in 400 s (Sonata, Siemens, Erlangen,
Germany) and a surface coil 1H quadrature transceiver
(16). Subjects were positioned supine inside the magnet
with the RF transceiver subjacent to their occipital lobe.
The protocol for each volunteer began with localizer mul-
tislice RARE images (TR  4.0 sec, TE  60 ms, echo train
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length  8, 256  128 matrix, two averages, 2 mm slice
thickness, five slices) for selection of a cubic volume of
interest (3  3  3 cm3) centered on the midsagittal plane
in the occipital lobe. Shimming of all first- and second-
order coils was achieved using FAST(EST)MAP (17), re-
sulting in water linewidths of 8–14 Hz (average 9 Hz).
Following adjustment of the spectrometer frequency, dif-
ference-editing using MEGA/BASING (14,18) was imple-
mented as described below.
MEGA-PRESS difference editing (14) was applied (Fig.
1) to edit for the cysteine -CH2 resonances of GSH
(2.95 ppm), which are J-coupled to the cysteine -CH
resonance (4.56 ppm). The three slice selective pulses in
conjunction with the lightest shaded gradients selected the
standard localized PRESS coherences (Fig. 1). The darkest
shaded crusher gradients also accounted for rewinding of
the excitation gradient. 1 was minimized (7.5 ms) for
optimal refocusing. The key editing components were the
selective inversion pulses (single banded 20 ms Gaussian
shape with a bandwidth of 75 Hz at half-height). When the
selective inversion pulses were applied (“on”) at the 1H
frequency of GSH cysteine -CH (4.56 ppm), evolution due
to J-coupling at GSH cysteine -CH2 (2.95 ppm) was par-
tially refocused at an echo time of 1/2J, as opposed to the
case when the selective inversion pulses were “off” (ap-
plied identically except at the resonance frequency of cys-
teine -CH plus 2000 Hz). Subtraction of “on”-scans from
“off”-scans resulted in exclusive detection of resonances
coupled to the region at 4.56 ppm. Therefore, the aspartyl
resonances of NAA at 2.45 and 2.67 ppm were coedited
with the cysteinyl resonance of GSH because they are
coupled to the -CH at 4.38 ppm, which falls within the
bandwidth of the editing pulse. Theoretical calculation of
the optimal echo time was complicated by nonequivalence
of the cysteine- protons of GSH. Therefore, the echo time
was varied between 60 and 100 ms experimentally in
phantoms and the maximum of the edited signal was
found at 68 ms (21 	 22). Additional water suppression
using VAPOR and outer volume saturation based on a
series of hyperbolic secant RF pulses (19) were adapted for
the human system (20) and incorporated prior to MEGA-
PRESS (not shown). Each subspectrum (NEX  1) was
stored separately in memory, then frequency- and phase-
corrected based on the single-shot NAA signal prior to
summation. Processing was performed using spectrometer
built-in software.
GSH concentration was quantified relative to coedited
aspartyl NAA (assumed at 10 mM) by using LCModel
analysis (15) applied to the edited spectra. Two basis spec-
tra were acquired using the same MEGA-PRESS differ-
ence-editing scheme (Fig. 1) as in vivo from two separate
phantoms (pH  7.1, 37° C) containing 5 mM NAA and
5 mM GSH, respectively. LCModel fitting was performed
over the spectral range from 2.0 and 3.5 ppm. Global
frequency referencing of the in vivo edited spectrum was
based on both model spectra and was constrained to
within 
0.2 ppm. Subsequently, the frequencies of edited
GSH and NAA were allowed to vary slightly (
0.004
ppm), independent of one another. The phase of the edited
spectrum was adjusted based on the unedited subspec-
trum. Some flexibility in the zero-order phase (
20°) was
left to LCModel for the fit. The relative signal contributions
were calibrated using an edited spectrum acquired from a
phantom containing equimolar (10 mM) GSH and NAA.
The accuracy of the ensuing quantitation was verified by
analyzing spectra acquired from four phantoms (pH  7.1,
37°C), all containing 10 mM NAA and 8 mM creatine (Cr),
but each containing a different concentration of GSH
(1 mM, 2.5 mM, 5 mM, and 10 mM). Furthermore, to
confirm the concentration of GSH, the GSH signal was also
quantified relative to the integral of the Cr methyl peak at
3.03 ppm measured in the subspectra using built-in spec-
trometer software. This procedure was calibrated in a
phantom containing 10 mM GSH, 8 mM Cr, and 10 mM
NAA (pH  7.1, 37°C) and validated by analyzing spectra
from three phantoms (pH  7.1, 37°C) all containing
10 mM NAA and 8 mM creatine (Cr), but each containing
a different concentration of GSH (1 mM, 2.5 mM, 5 mM).
RESULTS
Subspectra and the corresponding edited spectrum from
one volunteer are shown in Fig. 2. Note the strong NAA
signal in the subspectra, which was used for unambiguous
determination of offset (NAA was referenced to
2.009 ppm) and phase. Figure 2d is a single-shot spectrum
(i.e., NEX  1), illustrating that the SNR for NAA was
sufficient for frequency and phase correction of individual
acquisitions prior to summation.
The cysteine -CH2 resonance of GSH was unequivo-
cally and consistently detected at 2.95 ppm in all 12 in
vivo studies as judged from the consistent spectral pattern
at 2.95 ppm, mimicking that measured in an accordingly
line-broadened phantom spectrum (Fig. 3).
LCModel analysis of edited in vivo spectra was highly
successful, as illustrated in Fig. 4. The fit precisely repli-
cated the edited in vivo spectrum (Fig. 4). NAA was clearly
demarcated from GSH (Fig. 4), both of which have a com-
plex spectral pattern. The fit residual was at the level of
noise, consistent with the visual similarity of the in vivo
spectral pattern to that in phantoms (Figs. 3, 4). The GSH
FIG. 1. MEGA-PRESS pulse sequence designed for localization
and editing of cysteinyl  protons of GSH (2.95 ppm). Slice-selective
pulses and light gradients accomplish localization. Darkest crusher
gradients also account for rewind of excitation gradient. Main edit-
ing components are (single-banded 20 ms gauss with a bandwidth
of 75 Hz) selective inversion pulses, applied at the chemical shift of
the cysteinyl  protons of GSH (4.56 ppm), which are switched on
and off alternately. Labeled MEGA gradients (G1, G2, and G3) are for
suppression of unwanted signal (14).
20 Terpstra et al.
concentration determined using the ratio of fitted GSH to
fitted NAA (set to 10 mol/g) as described in Subjects and
Methods was 1.3 
 0.2 mol/g (mean 
 SD, n  12). The
Cramer-Rao bounds for GSH were 9% and 2% for NAA on
average, and never higher than 10% for GSH. The influ-
ence of changes in editing efficiency due to changes in
frequency, which were monitored during each scan, was
minimal (negligible on average, 7% at most).
Spectra acquired from the series of phantoms containing
1, 2.5, 5, and 10 mM GSH plus 8 mM Cr and 10 mM NAA
are illustrated in Fig. 5, along with typical in vivo spectra.
From the comparison of the in vivo spectrum with the
phantom spectra it was apparent that the in vivo GSH
concentration was in the range of 1–2 mol/g.
Quantification of GSH with respect to Cr measured in
the subspectra resulted in a concentration of 1.0 

0.2 mol/g (mean 
 SD, n  12) relative to 8 mol/g Cr.
Additional simplistic attempts at estimating GSH concen-
tration relative to Cr using integration techniques were
undertaken in order to affirm accurate quantification and
provided estimates in the range of 1–2 mM with higher
standard deviation.
DISCUSSION
The similarity of line shape, position, phase, and spectral
pattern between in vivo and in vitro (phantom) spectra
demonstrates the unequivocal detection of the cysteine
-CH2 resonance of GSH at 2.95 ppm (Figs. 3, 5). The
estimated GSH concentration, 1.3 
 0.2 mol/g, is in good
agreement with the estimated concentration from the first
edited detection of GSH in human brain (9,10). The
present study is in excellent agreement with preliminary
estimates of human GSH concentration obtained using in
vivo 1H NMR spectra (7 T) and LCModel at short echo
times, reporting 1.6 
 0.1 mol/g (13). Studies have re-
ported GSH concentrations in human brain using bio-
chemical methods with the following values: 1.2 

0.2 mol/g (21), 1–10 mM (22), and 1–3 mM (5). Our
study is in excellent agreement with the lower end of these
concentrations, previous NMR measurements, and natural
abundance 13C NMR estimations (unpubl. obs.). It is note-
worthy that the coefficient of variation in the present study
(15%) using MEGA-PRESS at 4 T is smaller than the 40%
scatter of the GSH/water ratio by double quantum coher-
ence filtering at 1.5 T (9). LCModel analysis and difference
editing with MEGA-PRESS at 4 T has greatly reduced the
variability compared to prior results obtained from edited
detection of GSH. The quantification of GSH in edited
spectra depends on the relative transverse relaxation rates
between GSH, Cr, and NAA aspartyl resonances, which
were assumed to be identical in this study. Nevertheless,
the concentration obtained in this study is similar to that
obtained from human short echo time (TE  6 ms) spectra
using LCModel analysis (13), and to short echo time ani-
mal studies (6), where T2 relaxation effects are expected to
have a negligible effect on quantification.
Determination of the area under the cysteine -CH2 GSH
resonance at 2.95 ppm using standard integration was
complicated by the proximity of coedited resonances, po-
FIG. 3. Consistent detection of GSH in difference-edited MEGA-
PRESS spectra. Twelve edited in vivo spectra (TR  4.5 sec, TE 
68 ms, NEX 256 or 512) and one edited spectrum from a phantom
(top) containing equimolar NAA and GSH (TR  4.5 sec, TE 
68 ms, NEX  512) with a concentration of 5 mM. The dashed line
indicates the chemical shift (2.95 ppm) of the edited GSH multiplet.
FIG. 2. In vivo 1H NMR spectroscopy of GSH using MEGA-PRESS.
a: In vivo subspectrum acquired in the presence of the frequency-
selective editing pulse and (b) in the absence of the editing pulses
(TR  4.5 sec, TE  68 ms, NEX  256 each). c: Difference
spectrum resulting from subtraction of a from b. d: Subspectrum
from the same dataset (NEX  1).
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tential subtraction artifacts, and the heavily modulated
pattern of the edited GSH resonance. These complications
persisted despite the inherent benefits of measurement at
high field strength (4 T) where the impact of subtraction
artifacts at Cr and coedited NAA were reduced due to the
increased spectral separation between these metabolites.
Instead, LCModel analysis provided an unbiased and un-
ambiguous approach for separating the GSH resonance
from both coedited NAA and the small subtraction artifact
near the intense Cr resonance. This novel application of
LCModel differed from prior applications in that a very
small number (two) of metabolites were included in the
basis set. LCModel performed extremely well despite such
limited input. This was attributed, in part, to the unique
spectral pattern resulting from J-modulation at the long
echo times characteristic of edited spectra. Implementa-
tion of LCModel resulted in increased precision of quan-
tification. Although the coedited NAA resonances from the
aspartyl methylene were much less intense than the sub-
spectral Cr resonance, it was interesting to note that the
standard deviation of the ratio of GSH to NAA using LC-
Model was approximately 8% less than that obtained from
measuring GSH relative to Cr by manual integration.
In the edited spectra (Fig. 3), additional intensities were
observed, suggesting that more coherences were excited.
For example, the resonance near 3.18 ppm can in principle
indicate a subtraction artifact from the choline singlet co-
herence. However, the consistent, nondispersive spectral
pattern suggests that this peak may arise from a coedited
resonance, potentially homocarnosine, but the assignment
of this resonance warrants further investigation. Further
candidates for coediting include: phosphocholine and
glycerophosphocholine, which couple to resonances close
to the bandwidth of the frequency-selective editing pulses.
The resonances at 1.24 and 1.43 ppm most likely arise
from macromolecule (M2 and M3) coherences generated as
a result of a partially excited connectivity at 4.23 and
4.3 ppm, respectively (23). Signal contributions from
-CH2 GABA near 3.0 ppm are unlikely, as the pulses
designed for editing GSH do not excite resonances coupled
to -CH2 GABA.
The similarity between in vitro and in vivo GSH spectra
suggests that macromolecule (MM) resonances did not
contribute to the edited GSH signal. Furthermore, MMs
resonate at a slightly different location, at 2.98 ppm (11),
which is, at 4 T, 5 Hz downfield relative to GSH. Finally,
the coupling partners of the macromolecule resonance at
3 ppm detected in the human brain resonate at 1.72 and
3.32 ppm (23), which are not within the bandwidth of the
selective editing pulse used for the detection of GSH.
While correcting the FIDs on an individual basis for
phase and frequency improved the subtraction errors in
FIG. 4. LCModel analysis of a representative edited spectrum (TR
4.5 sec, TE  68 ms, NEX  512). Top: fit residual. Bottom: LC-
Model analysis including: total fit, GSH component of fit, and NAA
component of fit.
FIG. 5. Edited (difference) and corresponding sub-
spectra (sum) acquired from: four phantoms, all
containing 10 mM NAA and 8 mM Cr, but each
containing a different concentration of GSH (1 mM,
2.5 mM, 5 mM, and 10 mM) (top), and a typical in
vivo volume of interest (bottom). Relative signal
contributions confirm an in vivo GSH concentration
of 1 mM.
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the edited spectra, a persistent dispersive subtraction error
was detected for the NAA methyl resonance. However,
since the methyl NAA is well resolved from the region
around 3 ppm, this subtraction error did not interfere with
the detection of the edited GSH resonance at 2.95 ppm.
CONCLUSIONS
In conclusion, the potential of edited 1H MRS for the
detection of GSH was confirmed with difference editing,
and the quality of in vivo GSH spectra was improved
compared to previous studies, therefore establishing the
unequivocal detection of GSH in the human brain. The
frequency and phase information contained in the sub-
spectra provided an unbiased reference for the frequency
and phase of the edited GSH spectrum. The feasibility of
LCModel analysis of edited spectra was demonstrated.
Precision of quantitative signal contribution was increased
through utilization of LCModel, adding greatly to the
quantification of in vivo GSH concentration using spectral
editing.
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